Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of the efficacy and safety of levofloxacin eye drops and pranoprofen gel in the treatment of bacterial conjunctivitis in the real world.

Pakistan journal of pharmaceutical sciences·2025

Same author

Molecular mechanisms of α-conotoxin [S9K]TxID selectively targeting the rat α3β4 nicotinic acetylcholine receptor.

International journal of biological macromolecules·2025

Same author

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study.

Nature communications·2025

Same author

Human TMC1 and TMC2 are mechanically gated ion channels.

Neuron·2024

Same author

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.

mAbs·2024

Same author

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin's lymphoma.

mAbs·2024

Search research articles

Related Experiment Video

Updated: May 31, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Emerging antibody combinations in oncology.

Stephen J Demarest¹, Kandasamy Hariharan, Jianying Dong

¹Biogen Idec, San Diego, CA, USA. demarestsj@lilly.com

|June 24, 2011

Summary

Monoclonal antibodies (mAbs) show promise in cancer treatment but face resistance. Combining antibody therapies targeting multiple pathways may improve treatment efficacy and durability for better patient outcomes.

Area of Science:

Oncology
Immunology
Pharmacology

Background:

Monoclonal antibodies (mAbs) are a key therapeutic strategy for human diseases, particularly in oncology.
Current anti-cancer antibody therapies target growth factors, angiogenesis, induce apoptosis, or block immune checkpoints.
Tumor complexity and pathway redundancy often lead to treatment resistance, limiting curative potential.

Purpose of the Study:

To review emerging antibody therapeutic combinations for cancer treatment.
To explore strategies for improving the efficacy and durability of antibody-based therapies.
To discuss combinations targeting single or multiple biological pathways.

Main Methods:

Literature review of antibody therapeutics in oncology.
Analysis of combination strategies for monoclonal antibodies.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Experiment Videos

Last Updated: May 31, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Discussion of therapeutic mechanisms including immunomodulation and angiogenesis inhibition.

Main Results:

Few antibodies are curative due to tumor biological complexities and resistance mechanisms.
Combinations of antibody therapeutics are emerging to enhance treatment effectiveness.
Strategies involve combining antibodies within a single pathway or across multiple pathways.

Conclusions:

Combining monoclonal antibodies offers a promising approach to overcome treatment resistance in cancer.
Targeting multiple biological pathways simultaneously or sequentially can improve therapeutic outcomes.
Further research into antibody combinations is crucial for advancing cancer treatment.